Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MetaboTract

Financiado

Improving cellular cancer immunotherapy using chemotactic metabolite receptors

Chimeric antigen receptor T cell (CAR T) cellular immunotherapy has revolutionized treatment for patients with hematological cancers, but largely failed to provide benefits for patients with solid tumors. Ineffective CAR T migrati... ver más

31/08/2026

LMU MUENCHEN

190K€

Presupuesto del proyecto: 190K€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-21

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

LMU MUENCHEN

189.69K€ | Lider

Proyectos interesantes

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

REACT-DC Breaking oncometabolites dynamics for next-generation dendri... 2M€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

GlycoTherapy New frontiers in advanced glycotherapy for cancer 2M€ Cerrado

PLEC2022-009319 Descubrimiento y desarrollo temprano de nuevos activadores d... 380K€ Cerrado

PID2019-108989RB-I00 EL MICROAMBIENTE TUMORAL COMO DIANA PARA EL DESARROLLO DE IN... 157K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 40 meses Fecha Inicio: 2023-04-21
Fecha Fin: 2026-08-31

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN

TRL 4-5

Presupuesto del proyecto 190K€

Descripción del proyecto Chimeric antigen receptor T cell (CAR T) cellular immunotherapy has revolutionized treatment for patients with hematological cancers, but largely failed to provide benefits for patients with solid tumors. Ineffective CAR T migration into solid tumors caused by the lack of recruitment signals, including chemokines, is a key gap for current cellular immunotherapies. The very common accumulation of metabolites in tumors provides a yet unrecognized opportunity to guide immune cells into tumors. Therefore, my overall research objective for this project is to generate and use novel chemotactic metabolite receptors (MetaboTract) to enhance the efficacy of CAR T and natural killer (NK) in solid tumors. This innovative approach is expected to impact the therapeutic options for cancer patients with poorly infiltrated tumors and enhance the EU’s competitiveness in the rapidly expanding market of cellular immunotherapies. Applying the gained knowledge on CAR NK cells could additionally reduce treatment costs and accelerate deployment of cellular therapies to patients. During the MSCA fellowship, I will learn vital new skills including cell migration assays, in vivo models for immunotherapies, project management, exploitation, and leadership in the renowned laboratory of Prof. Sebastian Kobold at the Ludwig-Maximilians-University (LMU) in Munich. The expertise of Prof. Kobold’s lab with chemokine receptor CAR T cells and in vivo models together with my complementary skills in cellular immunology, NK cells, imaging, and bioinformatics gives the project a high likelihood of success. The publication of the results, the gained knowledge and skills, and the demonstrated mobility will strengthen my scientific independence and help me achieve my career goal of becoming a research group leader in cellular cancer immunotherapy.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores